Charishma Bhimineni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Charishma Bhimineni has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Atousa Jahanshahi
Jefferson Einstein Montgomery Hospital, 559 West Germantown Pike, East Norriton, PA 19403, USA
1 shared publication - Bal Krishna Subedi
Department of Internal Medicine, Einstein Medical Center Montgomery, East Norriton, PA, USA
1 shared publication - Daniel Bitetto
Department of Internal Medicine, Jefferson Einstein Montgomery Hospital (Einstein Medical Center Montgomery), East Norriton, PA, USA
1 shared publication - Katherine Quiza
Jefferson Einstein Montgomery Hospital, 559 West Germantown Pike, East Norriton, PA 19403, USA
1 shared publication - Shivani Modi
Jefferson Einstein Montgomery Hospital, 559 West Germantown Pike, East Norriton, PA 19403, USA
1 shared publication
Latest Publications
- Open Access
- 25 August 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (9) , 477
The Role of Insulin Resistance in Cancer
Insulin resistance (IR) is a prevalent metabolic condition characterized by reduced cellular responsiveness to insulin and consequent hyperinsulinemia, and it is a key component of type 2 diabetes and metabolic syndrome. A growing body of evidence suggests IR is a critical accomplice in the pathogenesis of various cancers. This review synthesizes evidence on underlying molecular mechanisms, including the integrated roles of the insulin/IGF system, chronic inflammation, metabolic reprogramming, and mitochondrial dysfunction. This review proposes that metabolic dysregulation should be viewed as a modifiable oncogenic force. This perspective illuminates new pathways for understanding cancer development and offers promising avenues for prevention and therapeutic intervention.
- 25 August 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (9) , 477
Open AccessThe Role of Insulin Resistance in Cancer
Insulin resistance (IR) is a prevalent metabolic condition characterized by reduced cellular responsiveness to insulin and consequent hyperinsulinemia, and it is a key component of type 2 diabetes and metabolic syndrome. A growing body of evidence suggests IR is a critical accomplice in the pathogenesis of various cancers. This review synthesizes evidence on underlying molecular mechanisms, including the integrated roles of the insulin/IGF system, chronic inflammation, metabolic reprogramming, and mitochondrial dysfunction. This review proposes that metabolic dysregulation should be viewed as a modifiable oncogenic force. This perspective illuminates new pathways for understanding cancer development and offers promising avenues for prevention and therapeutic intervention.